RSS   Newsletter   Contact   Advertise with us
Post Online Media

Flexion Therapeutics announces two key corporate appointments

Flexion TherapeuticsFlexion Therapeutics, Inc., a specialty pharmaceutical company, announced that it has made two key appointments to its leadership team.
Article continues below

READ MORE Flexion adds Scott Canute to board of directors

Carolyn Beaty Scimemi, an experienced compliance and legal professional, was named as Chief Compliance Officer.

Ms. Scimemi has more than a decade of experience working with legal and contractual matters for publicly traded biopharmaceutical companies in both pre-approval and in commercial stages of product development.

She joined Dyax in 2009 and most recently served as Vice President, Associate General Counsel & Chief Compliance Officer.

Previously, she was Associate Director of Legal Affairs and Compliance for Oscient Pharmaceuticals in Waltham, MA, an associate attorney at Palmer and Dodge LLP in Boston, and a contracts administrator at the Massachusetts Institute of Technology.

She earned her JD and Bachelor's of Science degrees from Suffolk Law School in Boston. Adam Muzikant, Ph.D., a veteran biotechnology deal negotiator and strategist, as Vice President, Business Development.

Dr. Muzikant joins Flexion with 18 years of hands-on leadership experience in biotechnology and specialty pharmaceuticals companies, and consulting firms.

Most recently, he was Vice President, Business Development at Synta Pharmaceuticals in Lexington, Mass., where he led the strategic transaction process culminating in a merger with Madrigal Pharmaceuticals.

Prior to Synta, Dr. Muzikant held business development leadership positions at AMAG Pharmaceuticals, Inotek Pharmaceuticals, EPIX Pharmaceuticals, and Predix Pharmaceuticals, and also performed transaction/strategic advisory work for biotechnology and pharmaceutical clients with Locust Walk Partners.

Prior to moving into business development, Dr. Muzikant led an anti-arrhythmia drug discovery program at Predix targeting ion channels.

He received his Ph.D. in biomedical engineering from Duke University, and a Bachelor's degree in bioengineering from the University of California, San Diego.

 LATEST MOVES FROM Massachusetts 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy